Pharmaceuticals
We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising.
Explore our sectors
Meet our lawyers
News and insights
Publications: 20 March 2024
Allen & Overy’s Nicole Daley on the rebound in M&A activity in the pharma industry
Nicole Daley, life sciences and M&A partner at Allen & Overy, discussed the steady pickup in M&A in the pharma industry after years of underperformance with PharmaVoice.
News: 09 February 2024
Allen & Overy advises Sartorius group on EUR1.4bn equity raising
Frankfurt am Main - Allen & Overy has advised the Sartorius group on equity raisings with a total volume of EUR1.4bn. The transaction comprised the placement of 613,497 preference shares currently…
News: 09 February 2024
Allen & Overy advises Exponent on investment in Chanelle Pharma
LONDON – Allen & Overy (A&O) has advised Exponent Private Equity LLP (Exponent), a leading European private equity firm, on its investment in Ireland's largest manufacturer of generic pharmaceuticals,…
Blog Post: 02 February 2024
The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products.